SAGE Therapeutics Inc SG7-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 3:57 PM CEST
11.94quote price arrow down-1.13 (-8.65%)
52 week range
11.45 - 55.00
Loading...
  • Open12.19
  • Day High12.19
  • Day Low11.94
  • Prev Close12.00
  • 52 Week High55.00
  • 52 Week High Date06/12/23
  • 52 Week Low11.45
  • 52 Week Low Date04/17/24

Key Stats

  • Market Cap838.94M
  • Shares Out60.18M
  • 10 Day Average Volume191.11
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-40

KEY STATS

  • Open12.19
  • Day High12.19
  • Day Low11.94
  • Prev Close12.00
  • 52 Week High55.00
  • 52 Week High Date06/12/23
  • 52 Week Low11.45
  • 52 Week Low Date04/17/24
  • Market Cap838.94M
  • Shares Out60.18M
  • 10 Day Average Volume191.11
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-40

RATIOS/PROFITABILITY

  • EPS (TTM)-7.78
  • P/E (TTM)-1.53
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On SAGE Therapeutics Inc

 

Profile

MORE
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a...
Geno Germano
Independent Chairman of the Board
Barry Greene
President, Chief Executive Officer, Director
Kimi Iguchi
Chief Financial Officer, Treasurer
Address
215 1st St
Cambridge, MA
02142-1213
United States